July 07, 2008
Press Release no.1
NSE
completes its 2098th
Normal Settlement
The Exchange has successfully
completed its 2098th Normal Settlement (Rolling T+2 following SEBI
directive) since inception i.e., Settlement Numbers N – 2008126 on July 7, 2008.
The settlement statistics is as follows:
Particulars
|
Values
|
|
|
N – 2008126
|
|
Total traded quantity
(lakhs) |
6320.67 |
|
Total traded value (Rs. In
Crores) |
12822.16 |
|
Total value of the
settlement (Securities) (Rs. In Crores) |
2884.27 |
|
Total value of the settlement
(Funds) (Rs. In Crores) |
1140.88 |
Shortages
for the settlement
|
0.12% |
|
% of Delivery ( No. of shares deliverable / No.
of shares traded ) |
18.79% |
Retail Debt Market have completed its 1372nd settlement
detail of which is as follows:
|
Settlement No. |
Traded Value |
Settlement Value |
|
|
|
|
Securities |
Funds |
|
D- 2008126 |
NIL |
NIL |
NIL |
Press Release no.2
News about Pyramid Saimira Theatre
Limited
The media had reports that US based Regal
Entertainment group, and private equity funds such as Brain Capital, Goldman
Sachs and Texas Pacific Group are in talks with the promoters of the company to
pick around 14% stake in Pyramid Saimira Theatre Limited.
The Exchange, in order to verify the accuracy or
otherwise of the information reported in the media and to inform the market
place so that the interest of the investors is safeguarded, had written to the
officials of the company.
Pyramid Saimira Theatre Limited has vide its letter
inter-alia stated, "We wish to inform you that the company does not
subscribe to any of the news expressed in those columns and the company has
nothing to do with this information, which seems to be speculative report
emanating from the media."
Press Release no.3
News about Biocon Limited
The media had reports that Biocon Limited may hive
off its research and development activity to a separate entity as part of its
focus on innovation.
The Exchange, in order to verify the accuracy or
otherwise of the information reported in the media and to inform the market
place so that the interest of the investors is safeguarded, had written to the
officials of the company.
Biocon Limited has vide its letter inter-alia
stated, "We wish to inform that the company, with a view to achieve great
focus on its research programmes is proposing to set up a new R&D entity
for discovery and innovative drug development initiatives. The creation of the
new entity is under way and further modalities are being worked out. Further
the proposal of setting up a